Canaccord Maintains Hold, $23 Target on Genomic Health

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Canaccord reiterates its Hold rating and $23 target on Genomic Health (NASDAQ: GHDX) as the company's DCIS test is validated at San Antonio breast cancer meeting. Canaccord says, “DCIS study met primary endpoint. The DCIS validation study demonstrated that 75% of patients have a low DCIS score and have only a 12% chance of recurrence, while high DCIS scores had a 27% likelihood of recurrence. …DCIS market estimates. With approximately 40,000 patients diagnosed with DCIS in the US each year, we estimate the opportunity at $130M.” GHDX closed at $28.47 per share on Tuesday.

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!